Drug Profile
Cannabinol topical - InMed Pharmaceuticals
Alternative Names: INM 755; INM-750Latest Information Update: 05 Oct 2023
Price :
$50
*
At a glance
- Originator InMed Pharmaceuticals
- Class Antiallergics; Antiglaucomas; Cannabinoids; Neuroprotectants; Phytotherapies; Skin disorder therapies
- Mechanism of Action Apoptosis inhibitors; Cannabinoid receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes - Epidermolysis bullosa
Highest Development Phases
- Phase II Epidermolysis bullosa
Most Recent Events
- 29 Sep 2023 Cannabinol topical - InMed Pharmaceuticals is available for licensing as of 29 Sep 2023. http://sntpseditorial/adis2000www/script/citation/citationmain.asp?Adnm=
- 26 Jun 2023 Interim efficacy data from a phase I 755-101-HV Epidermolysis Bullosa released by InMed Pharmaceuticals
- 26 Jun 2023 Interim efficacy data from a phase II 755-201-EB Epidermolysis Bullosa released by InMed Pharmaceuticals